<DOC>
	<DOCNO>NCT00915018</DOCNO>
	<brief_summary>This study investigate effect experimental drug ( neratinib ) combination paclitaxel versus trastuzumab combination paclitaxel treatment woman receive previous treatment erbB-2-positive locally recurrent metastatic breast cancer . The study compare effectiveness regimen shrink tumor extend life woman erbB-2 ( HER2 ) positive breast cancer . The study also compare safety two regimen well quality life subject receive either regimen .</brief_summary>
	<brief_title>Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>ErbB2 positive locally recurrent metastatic breast cancer Eastern Cooperative Oncology Group ( ECOG ) 02 Measurable disease Availability tumor tissue HER2 status confirmation Prior systemic anticancer therapy endocrine therapy locally recurrent metastatic disease Prior erbB2 inhibitor trastuzumab lapatinib neoadjuvant adjuvant set Progression/recurrence within 12 month completion adjuvant neoadjuvant therapy history heart disease history gastrointestinal disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>ErbB-2 positive advance breast cancer</keyword>
</DOC>